261 related articles for article (PubMed ID: 15668707)
21. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
22. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study.
Hallak R; Mueller J; Lotter O; Gansauge S; Gansauge F; el-Deen Jumma M; Montenarh M; Safi F; Beger H
Int J Oncol; 1998 Apr; 12(4):785-91. PubMed ID: 9499437
[TBL] [Abstract][Full Text] [Related]
23. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
24. Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer.
Caldes T; Iniesta P; Vega FJ; de Juan C; Lopez JA; Diaz-Rubio E; Fernandez C; Cerdan J; Balibrea JL; Benito M
Oncology; 1998; 55(3):249-57. PubMed ID: 9560058
[TBL] [Abstract][Full Text] [Related]
25. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.
Slebos RJ; Baas IO; Clement M; Polak M; Mulder JW; van den Berg FM; Hamilton SR; Offerhaus GJ
Br J Cancer; 1996 Jul; 74(2):165-71. PubMed ID: 8688317
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
[TBL] [Abstract][Full Text] [Related]
28. p53 mutation found to be a significant prognostic indicator in distal colorectal cancer.
Okubo R; Masuda H; Nemoto N
Oncol Rep; 2001; 8(3):509-14. PubMed ID: 11295071
[TBL] [Abstract][Full Text] [Related]
29. Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.
Grabowski P; Sturm I; Schelwies K; Maaser K; Buhr HJ; Dörken B; Zeitz M; Daniel PT; Scherübl H
Int J Colorectal Dis; 2006 Apr; 21(3):221-30. PubMed ID: 16485142
[TBL] [Abstract][Full Text] [Related]
30. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of P53 mutations in rectal carcinoma.
Rebischung C; Gérard JP; Gayet J; Thomas G; Hamelin R; Laurent-Puig P
Int J Cancer; 2002 Jul; 100(2):131-5. PubMed ID: 12115559
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.
Zellars RC; Hilsenbeck SG; Clark GM; Allred DC; Herman TS; Chamness GC; Elledge RM
J Clin Oncol; 2000 May; 18(9):1906-13. PubMed ID: 10784631
[TBL] [Abstract][Full Text] [Related]
33. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer.
Pan ZZ; Wan DS; Chen G; Li LR; Lu ZH; Huang BJ
World J Gastroenterol; 2004 Dec; 10(24):3688-90. PubMed ID: 15534934
[TBL] [Abstract][Full Text] [Related]
34. Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
Colomer A; Erill N; Verdú M; Roman R; Vidal A; Cordon-Cardo C; Puig X
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):130-7. PubMed ID: 12777996
[TBL] [Abstract][Full Text] [Related]
35. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
36. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
37. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
[TBL] [Abstract][Full Text] [Related]
38. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers.
Hamada M; Fujiwara T; Hizuta A; Gochi A; Naomoto Y; Takakura N; Takahashi K; Roth JA; Tanaka N; Orita K
J Cancer Res Clin Oncol; 1996; 122(6):360-5. PubMed ID: 8642047
[TBL] [Abstract][Full Text] [Related]
39. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
40. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
